相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance
Brian Kwok et al.
BLOOD (2015)
ELTROMBOPAG FOR LOW TO INTERMEDIATE-2 RISK MYELODYSPLASTIC SYNDROME
D. Townsley et al.
LEUKEMIA RESEARCH (2015)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients
Emnet Wassie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Loss of Blast Heterogeneity in Myelodysplastic Syndrome and Other Chronic Myeloid Neoplasms
Dragan Jevremovic et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Results of a Randomized, Double-Blind Study of Romiplostim Versus Placebo in Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome and Thrombocytopenia
Aristoteles Giagounidis et al.
CANCER (2014)
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
F. Traina et al.
LEUKEMIA (2014)
The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS
A. M. Aalbers et al.
LEUKEMIA (2014)
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS
A. Porwit et al.
LEUKEMIA (2014)
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
Asmita Mishra et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)
Rie Ohba et al.
ANNALS OF HEMATOLOGY (2013)
Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification
P. Font et al.
ANNALS OF HEMATOLOGY (2013)
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Omar Abdel-Wahab et al.
BLOOD (2013)
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
Frederik Damm et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation
Su Jung Song et al.
CELL STEM CELL (2013)
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
Maria Teresa Voso et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics
Wolfgang Kern et al.
HAEMATOLOGICA (2013)
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
John Koreth et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database
Maria Teresa Voso et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
Mrinal M. Patnaik et al.
BLOOD (2012)
Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts
Mrinal M. Patnaik et al.
BLOOD (2012)
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
Felicitas Thol et al.
BLOOD (2012)
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
Valeria Visconte et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors
Stefani Parmentier et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients
M. M. Patnaik et al.
LEUKEMIA (2012)
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
U. Germing et al.
LEUKEMIA (2012)
Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Dusseldorf MDS registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2012)
Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia
Guilin Tang et al.
LEUKEMIA RESEARCH (2012)
Vitamin B-12-Responsive Pancytopenia Mimicking Myelodysplastic Syndrome
Myungshin Kim et al.
ACTA HAEMATOLOGICA (2011)
Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
Lewis R. Silverman et al.
CANCER (2011)
Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Felicitas Thol et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care-SAKK 33/99
Jakob R. Passweg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
M. Mallo et al.
LEUKEMIA (2011)
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
M. J. Walter et al.
LEUKEMIA (2011)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R. Itzykson et al.
LEUKEMIA (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Use of Erythropoietic Stimulating Agents in Myelodysplastic Syndromes
Valeria Santini
ONCOLOGIST (2011)
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
Robert P. Hasserjian et al.
BLOOD (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study
Emilio Paolo Alessandrino et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The Epidemiology of Myelodysplastic Syndromes
Mikkael A. Sekeres
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko et al.
NATURE (2010)
Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype
Daniel T. Starczynowski et al.
NATURE MEDICINE (2010)
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L. Greenberg et al.
BLOOD (2009)
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder
Claude Preudhomme et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach
John M. Bennett et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
Hematological manifestations of copper deficiency: a retrospective review
Thorvardur R. Halfdanarson et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Severe vitamin B12 deficiency resulting in pancytopenia, splenomegaly and leukoerythroblastosis
Thorvardur R. Halfdanarson et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
Elaine M. Sloand et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Benjamin L. Ebert et al.
NATURE (2008)
A prognostic score for patients with lower risk myelodysplastic syndrome
G. Garcia-Manero et al.
LEUKEMIA (2008)
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Andres O. Soriano et al.
BLOOD (2007)
Myocardial iron loading by magnetic resonance imaging T2*in good prognostic myelodysplastic syndrome patients on long-term blood transfusions
Joseph Chacko et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Down myeloid disorders: A paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis
Paresh Vyas et al.
EARLY HUMAN DEVELOPMENT (2006)
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia-Manero et al.
BLOOD (2006)
Current concepts in the pathophysiology and treatment of aplastic anemia
Neal S. Young et al.
BLOOD (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
Additional prognostic value of bone marrow histology in patients subclassified according to the international prognostic scoring system for myelodysplastic syndromes
E Verburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Dyskeratosis congenita in all its forms
I Dokal
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
